Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain

NCT04333576 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04333576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 10, 2020
Completion date
July 31, 2027
Enrollment
800 (estimated)
Sites
179

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis